ERBB2 and neoplasm: We then evaluated the likelihood of pCR following different anti-HER2 therapies (chemotherapy plus single anti-HER2 therapy or chemotherapy plus dual anti-HER2 therapy) for HER2-positive tumours (Fig. 1B).